Physician profile
Alfred Lee
NPI 1689675837
$7,355.15
in general payments reported to CMS, 2019-2025
24 companies · $23.96 in 2025
The $23.96 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $743 · 2021: $1,808 · 2022: $2,073 · 2023: $1,861 · 2024: $13.41 · 2025: $23.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.58 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,682.09 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $760.48 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $667.32 | 2019-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $538.49 | 2019-2023 | Stelara |
| Genzyme Corporation | $494.06 | 2022-2023 | |
| Gilead Sciences, INC. | $459.46 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $358.73 | 2020-2023 | Linzess |
| Pfizer INC. | $319.34 | 2019-2022 | |
| Celgene Corporation | $245.99 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $151.45 | 2022-2023 | Ibsrela |
| Allergan, INC. | $127.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $115.53 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $71.93 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $69.42 | 2021-2023 | Givlaari |
| Echosens North America, INC. | $62.25 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $59.66 | 2019-2023 | Ocaliva |
| Apollo Endosurgery US INC | $41.27 | 2022 | |
| Concordia Pharmaceuticals INC. | $26.02 | 2019 | |
| Qol Medical, LLC | $25.60 | 2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $23.00 | 2023 | Dupixent |
| W. L. Gore & Associates, INC. | $16.68 | 2021 | |
| Intra-Sana Laboratories | $13.58 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.41 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.